A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan

Yao Chi Chuang, Chih Chieh Lin, Po Ming Chow, Chi Shun Lien, Ke Hung Tsui, Chieh Lung Chou, Hsiang Ying Lee, En Meng, Hann Chorng Kuo

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: This study evaluated the efficacy and safety of imidafenacin 0.1 mg twice daily vs placebo for Taiwanese patients with overactive bladder (OAB) after a 12-week oral administration. Methods: This randomized, double-blind, placebo-controlled, two-arm, parallel-group, prospective study enrolled 118 patients across 11 study sites in Taiwan. Subjects were randomized to imidafenacin or placebo in a 2:1 ratio and entered the 12-week treatment period. At the subsequent visits, efficacy outcome measures and safety assessments were collected for analysis. The primary efficacy outcome was the change in the mean number of micturitions per day. Secondary endpoints included mean changes from baseline in urgency episodes and urge incontinence episodes per day and mean volume voided per micturition. Safety outcomes were also collected and compared between groups. Results: A total of 78 and 40 patients were allocated to the imidafenacin and placebo groups, respectively. Among them, 100 patients (imidafenacin, 65 and placebo, 35) completed the trial. Compared with placebo, imidafenacin was significantly better at reducing the number of micturitions per day (−1.29 ± 2.23 vs -0.46 ± 3.49, P =.0171) and reducing the mean number of urge incontinence episodes (−0.15 ± 0.52 vs 0.04 ± 0.50, P =.0386) at week 12. Adverse events were reported in 35 subjects (44.9%) and 16 (40%) in the imidafenacin and placebo groups, including constipation (n = 3, 4), dry mouth (n = 11, 2), and urinary tract infection (n = 7, 4), respectively. One patient in the imidafenacin group had mild dysuria. Conclusion: Imidafenacin demonstrated efficacy and safety in the treatment of OAB in Taiwanese patients.

Original languageEnglish
Pages (from-to)108-117
Number of pages10
JournalLUTS: Lower Urinary Tract Symptoms
Volume13
Issue number1
DOIs
Publication statusPublished - Jan 2021
Externally publishedYes

Keywords

  • adverse events
  • antimuscarinics
  • overactive bladder
  • pharmacotherapy

ASJC Scopus subject areas

  • Neurology
  • Urology

Fingerprint

Dive into the research topics of 'A double-blind, randomized, placebo-controlled, parallel study to evaluate the efficacy and safety of imidafenacin in patients with overactive bladder in Taiwan'. Together they form a unique fingerprint.

Cite this